891 related articles for article (PubMed ID: 26921031)
21. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
22. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
23. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
24. [Therapy for non-muscle invasive bladder cancer: HP-NAP].
D'Agostino D; Racioppi M; Filianoti A; Di Gianfrancesco L; Codolo G; Fassan M; Munari F; Rugge M; D'Elios MM; de Bernard M; Pagano F; Bassi P
Urologia; 2012; 79(2):142-8. PubMed ID: 22522462
[TBL] [Abstract][Full Text] [Related]
25. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Sankin A; Narasimhulu D; John P; Gartrell B; Schoenberg M; Zang X
Urol Oncol; 2018 Oct; 36(10):459-468. PubMed ID: 28495553
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
[TBL] [Abstract][Full Text] [Related]
27. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
[TBL] [Abstract][Full Text] [Related]
28. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
29. Intravesical BCG Induces CD4
Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
[TBL] [Abstract][Full Text] [Related]
30. Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer.
Tsuji S; Reil K; Nelson K; Proclivo VH; McGuire KL; Giacalone MJ
Cancer Immunol Res; 2022 Aug; 10(8):978-995. PubMed ID: 35679299
[TBL] [Abstract][Full Text] [Related]
31. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
[TBL] [Abstract][Full Text] [Related]
34. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS; Seo HK
Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
[TBL] [Abstract][Full Text] [Related]
36. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
37. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
39. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
Lattime EC; Gomella LG; McCue PA
Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
[TBL] [Abstract][Full Text] [Related]
40. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
